CriticalAntituberculous antibiotic×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
Rifampicin is a strong inducer of drug-metabolising enzymes, including CYP2C9, CYP2C19 and CYP3A4, and of the transporter P-glycoprotein (P-gp) (rifampicin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, exactly these enzymes, CYP2C19, CYP2C9 and CYP3A4, metabolise voriconazole (voriconazole SmPC, European Medicines Agency, EMA). Rifampicin 600 mg once daily lowered peak voriconazole concentration by an average of 93% and the area under the concentration–time curve (AUC) by 96% (voriconazole SmPC, EMA, and voriconazole label, US Food and Drug Administration, FDA). Even a doubled voriconazole dose of 400 mg every 12 hours does not restore adequate exposure while rifampicin is given (voriconazole label, FDA, pharmacokinetics section).
Symptoms
The drop in voriconazole levels causes no symptoms of its own: the only sign is that the fungal infection does not improve, because at such low levels voriconazole may lose its effect (voriconazole label, US Food and Drug Administration, FDA). Voriconazole is used mainly for progressive, potentially life-threatening fungal infections and for prophylaxis after haematopoietic stem cell transplantation (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). Both drugs can harm the liver. Hepatitis, cholestasis and fulminant liver failure, including fatal cases, have been reported with voriconazole (EMA). With rifampicin, cholestasis has been reported with itching, weakness, loss of appetite, nausea, vomiting, abdominal pain, yellow eyes or skin and dark urine (rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is contraindicated. The voriconazole documents forbid its use with rifampicin, and the Spanish rifampicin SmPC lists voriconazole among the drugs that must not be combined with rifampicin (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and voriconazole label, US Food and Drug Administration, FDA; rifampicin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). A higher dose does not solve the problem: even a doubled voriconazole dose does not give adequate levels with rifampicin (FDA). Another Spanish rifampicin SmPC is less strict and only says that the voriconazole dose may need adjusting when rifampicin is started or stopped (AEMPS). This does not change the contraindication in the voriconazole documents. No document says how long to wait after stopping rifampicin before starting voriconazole. The rifampicin SmPC warns that doses of other drugs may need changing after rifampicin is stopped as well (AEMPS). During voriconazole treatment, measure the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) at the start and at least weekly during the first month (EMA). During rifampicin treatment, measure liver enzymes and bilirubin before the start and at least monthly (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- AEMPS: Ficha técnica: Voriconazol (nº registro 80105), sección 4.3 (2026)– AEMPS, CIMA, nº registro 80105, revisión 04/2026, sección 4.3
- AEMPS: Ficha técnica: Rifampicina (nº registro 46029), secciones 4.3 y 4.5 (2026)– AEMPS, CIMA, nº registro 46029, revisión 04/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Rifampicina (nº registro 49034), sección 4.5 (2026)– AEMPS, CIMA, nº registro 49034, revisión 08/2026, sección 4.5
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5